Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) FCF Margin (2017 - 2025)

Historic FCF Margin for Lexaria Bioscience (LEXX) over the last 12 years, with Q3 2025 value amounting to 1518.68%.

  • Lexaria Bioscience's FCF Margin rose 7845000.0% to 1518.68% in Q3 2025 from the same period last year, while for Nov 2025 it was 1668.28%, marking a year-over-year decrease of 3459400.0%. This contributed to the annual value of 1483.88% for FY2025, which is 4065000.0% down from last year.
  • According to the latest figures from Q3 2025, Lexaria Bioscience's FCF Margin is 1518.68%, which was up 7845000.0% from 2059.74% recorded in Q2 2025.
  • Lexaria Bioscience's FCF Margin's 5-year high stood at 17.63% during Q3 2021, with a 5-year trough of 8708.21% in Q4 2021.
  • For the 5-year period, Lexaria Bioscience's FCF Margin averaged around 2218.03%, with its median value being 1495.57% (2024).
  • In the last 5 years, Lexaria Bioscience's FCF Margin crashed by -84344000bps in 2021 and then surged by 74130600bps in 2022.
  • Lexaria Bioscience's FCF Margin (Quarter) stood at 8708.21% in 2021, then skyrocketed by 85bps to 1295.15% in 2022, then surged by 40bps to 781.11% in 2023, then tumbled by -91bps to 1495.57% in 2024, then fell by -2bps to 1518.68% in 2025.
  • Its FCF Margin was 1518.68% in Q3 2025, compared to 2059.74% in Q2 2025 and 860.86% in Q1 2025.